Adial Pharmaceuticals Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Adial Pharmaceuticals's earnings have been declining at an average annual rate of -0.2%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually.
Anahtar bilgiler
-0.2%
Kazanç büyüme oranı
28.8%
EPS büyüme oranı
Pharmaceuticals Sektör Büyümesi | 6.0% |
Gelir büyüme oranı | n/a |
Özkaynak getirisi | -285.0% |
Net Marj | n/a |
Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Güncelleme yok
Recent updates
Adial Clinical Trial: A Fluff Or A Win?
Aug 22Adial Pharmaceuticals GAAP EPS of -$0.16 beats by $0.01
Aug 16Revisiting Adial Pharmaceuticals: EMA Approval For Alcohol Use Disorder Pill Is A Critical Catalyst
Jun 21Adial Pharmaceuticals shares +5% on receiving third patent for opioid use disorder candidate
Jan 11Adial Pharmaceuticals inks stock purchase agreement with Keystone Capital
Nov 25Gelir ve Gider Dağılımı
Adial Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 24 | 0 | -12 | 5 | 2 |
31 Mar 24 | 0 | -11 | 5 | 1 |
31 Dec 23 | 0 | -7 | 6 | 1 |
30 Sep 23 | 0 | -8 | 6 | 2 |
30 Jun 23 | 0 | -9 | 7 | 2 |
31 Mar 23 | 0 | -10 | 8 | 2 |
31 Dec 22 | 0 | -11 | 9 | 2 |
30 Sep 22 | 0 | -14 | 9 | 4 |
30 Jun 22 | 0 | -16 | 9 | 5 |
31 Mar 22 | 0 | -17 | 9 | 7 |
31 Dec 21 | 0 | -19 | 9 | 8 |
30 Sep 21 | 0 | -17 | 9 | 8 |
30 Jun 21 | 0 | -16 | 8 | 8 |
31 Mar 21 | 0 | -13 | 7 | 7 |
31 Dec 20 | 0 | -11 | 5 | 6 |
30 Sep 20 | 0 | -9 | 5 | 5 |
30 Jun 20 | 0 | -8 | 4 | 4 |
31 Mar 20 | 0 | -8 | 4 | 4 |
31 Dec 19 | 0 | -9 | 4 | 4 |
30 Sep 19 | 0 | -8 | 4 | 3 |
30 Jun 19 | 0 | -14 | 4 | 2 |
31 Mar 19 | 0 | -14 | 3 | 1 |
31 Dec 18 | 0 | -12 | 2 | 0 |
30 Sep 18 | 0 | -11 | 1 | 0 |
30 Jun 18 | 0 | -3 | 1 | 0 |
31 Mar 18 | 0 | -1 | 1 | 0 |
31 Dec 17 | 0 | -1 | 1 | 0 |
30 Sep 17 | 0 | -1 | 1 | 0 |
30 Jun 17 | 0 | -1 | 0 | 0 |
31 Mar 17 | 0 | 0 | 0 | 0 |
31 Dec 16 | 0 | 0 | 0 | 0 |
Kaliteli Kazançlar: ADIL is currently unprofitable.
Büyüyen Kar Marjı: ADIL is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: ADIL is unprofitable, and losses have increased over the past 5 years at a rate of 0.2% per year.
Büyüme Hızlandırma: Unable to compare ADIL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: ADIL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Özkaynak Getirisi
Yüksek ROE: ADIL has a negative Return on Equity (-284.95%), as it is currently unprofitable.